Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: CVKD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35.67
1 Year Target Price $35.67
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.4% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.41M USD | Price to earnings Ratio - | 1Y Target Price 35.67 |
Price to earnings Ratio - | 1Y Target Price 35.67 | ||
Volume (30-day avg) 2 | Beta 1.12 | 52 Weeks Range 5.70 - 22.90 | Updated Date 07/13/2025 |
52 Weeks Range 5.70 - 22.90 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -109.43% | Return on Equity (TTM) -208.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21047773 | Price to Sales(TTM) - |
Enterprise Value 21047773 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 1966680 | Shares Floating 1389731 |
Shares Outstanding 1966680 | Shares Floating 1389731 | ||
Percent Insiders 29.34 | Percent Institutions 7.52 |
Upturn AI SWOT
Cadrenal Therapeutics, Inc. Common Stock
Company Overview
History and Background
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular diseases. It was founded in 2020 and is working to advance tecarfarin, a novel therapy for the prevention of systemic thromboembolism (stroke) in patients with congenital antithrombin III deficiency (AT-III).
Core Business Areas
- Pharmaceutical Development: Focuses on the development of Tecarfarin for AT-III deficiency and related cardiovascular indications.
Leadership and Structure
The leadership team consists of seasoned executives in the pharmaceutical industry, with expertise in drug development and commercialization. The company structure is typical of a clinical-stage biotech company, with dedicated teams for R&D, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Tecarfarin: Tecarfarin is an investigational drug for the prevention of systemic thromboembolism (stroke) in patients with congenital antithrombin III deficiency (AT-III). It has not yet received regulatory approval and has no market share. Potential competitors include existing anticoagulant therapies like warfarin and direct oral anticoagulants (DOACs) such as Xarelto (JNJ) and Eliquis (BMY/PFE).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investment in R&D. The cardiovascular disease therapeutics market is large and growing due to the increasing prevalence of these conditions.
Positioning
Cadrenal Therapeutics is a niche player focused on a rare disease (AT-III deficiency). Its competitive advantage, if Tecarfarin is approved, would be providing a more tailored therapy for this specific patient population.
Total Addressable Market (TAM)
The TAM for AT-III deficiency is relatively small due to the rarity of the condition. Estimates vary but are likely in the tens to hundreds of millions of dollars annually. Cadrenal is positioning itself to capture a significant share of this niche market if Tecarfarin proves successful.
Upturn SWOT Analysis
Strengths
- Focus on a rare and unmet medical need.
- Potential for orphan drug designation and associated benefits.
- Experienced leadership team.
Weaknesses
- Reliance on a single product candidate (Tecarfarin).
- Clinical and regulatory risks associated with drug development.
- Limited financial resources typical of a small biotech company.
Opportunities
- Positive clinical trial results for Tecarfarin.
- Regulatory approval and commercialization of Tecarfarin.
- Expansion of Tecarfarin's use to other cardiovascular indications.
- Partnerships or acquisitions by larger pharmaceutical companies.
Threats
- Failure of Tecarfarin in clinical trials.
- Regulatory rejection of Tecarfarin.
- Competition from existing or new therapies.
- Difficulty in raising capital.
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- PFE
Competitive Landscape
Cadrenal Therapeutics faces competition from established pharmaceutical companies with marketed anticoagulant therapies. Its success depends on demonstrating Tecarfarin's superiority in treating AT-III deficiency.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal given the company's recent founding and focus on R&D.
Future Projections: Future growth is highly dependent on the successful development and commercialization of Tecarfarin. Analyst estimates are speculative at this stage.
Recent Initiatives: Recent initiatives include progressing Tecarfarin through clinical trials and securing funding to support R&D activities.
Summary
Cadrenal Therapeutics is a high-risk, high-reward clinical-stage biotech company focused on a niche market. Its success is contingent on the clinical trial results and regulatory approval of Tecarfarin. While the company is addressing an unmet need, it faces substantial competition and requires continued funding. Positive trial outcomes will significantly enhance its prospects, while failures could be detrimental.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cadrenal Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2023-01-20 | Chairman & CEO Mr. Quang X. Pham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.cadrenal.com |
Full time employees 4 | Website https://www.cadrenal.com | ||
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.